Jesse J Smith

Summary

Publications

  1. pmc Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
  2. doi request reprint A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
    Sarah K Knutson
    Epizyme, Inc, Cambridge, MA, USA
    Nat Chem Biol 8:890-6. 2012
  3. doi request reprint Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators
    Chi B Vu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:1275-83. 2009
  4. doi request reprint Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators
    Jean E Bemis
    Sirtris, a GSK Company, Cambridge, MA 01239, USA
    Bioorg Med Chem Lett 19:2350-3. 2009
  5. doi request reprint A687V EZH2 is a gain-of-function mutation found in lymphoma patients
    Christina R Majer
    Epizyme, Inc, 325 Vassar St, Cambridge, MA 02139, USA
    FEBS Lett 586:3448-51. 2012
  6. pmc Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3
    Lei Jin
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    Protein Sci 18:514-25. 2009
  7. pmc Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
  8. doi request reprint Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
    Scott R Daigle
    Epizyme, Inc, Cambridge, MA 02139, USA
    Cancer Cell 20:53-65. 2011

Collaborators

Detail Information

Publications8

  1. pmc Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo
    Jesse J Smith
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    BMC Syst Biol 3:31. 2009
    ....
  2. doi request reprint A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
    Sarah K Knutson
    Epizyme, Inc, Cambridge, MA, USA
    Nat Chem Biol 8:890-6. 2012
    ....
  3. doi request reprint Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators
    Chi B Vu
    Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA
    J Med Chem 52:1275-83. 2009
    ..The most potent analogue within this series, namely, compound 29, has demonstrated oral antidiabetic activity in the ob/ob mouse model, the diet-induced obesity (DIO) mouse model, and the Zucker fa/fa rat model...
  4. doi request reprint Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators
    Jean E Bemis
    Sirtris, a GSK Company, Cambridge, MA 01239, USA
    Bioorg Med Chem Lett 19:2350-3. 2009
    ..Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol...
  5. doi request reprint A687V EZH2 is a gain-of-function mutation found in lymphoma patients
    Christina R Majer
    Epizyme, Inc, 325 Vassar St, Cambridge, MA 02139, USA
    FEBS Lett 586:3448-51. 2012
    ..We propose that A687V EZH2 also leads to hypertrimethylation of H3K27 and may thus be a driver mutation in NHL...
  6. pmc Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3
    Lei Jin
    Sirtris, a GSK Company, 200 Technology Square, Cambridge, MA 02139, USA
    Protein Sci 18:514-25. 2009
    ..Thus, identification and characterization of the actual SIRT3 sequence should help resolve the debate about the nature of mouse SIRT3 and identify new mechanisms to modulate enzymatic activity...
  7. pmc Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
    Jill C Milne
    Sirtris Pharmaceuticals Inc, 790 Memorial Drive, Cambridge, Massachusetts 02139, USA
    Nature 450:712-6. 2007
    ..Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes...
  8. doi request reprint Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
    Scott R Daigle
    Epizyme, Inc, Cambridge, MA 02139, USA
    Cancer Cell 20:53-65. 2011
    ..Finally, in vivo administration of EPZ004777 leads to extension of survival in a mouse MLL xenograft model. These results provide compelling support for DOT1L inhibition as a basis for targeted therapeutics against MLL...